Clinicopathological Features and Survival Outcomes of Metaplastic Breast Carcinoma – An Observational Multi-Centric Study

References

• Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries - Sung - 2021 - CA: a cancer journal for clinicians. Wiley Online Library; 2022. Available from: doi:10.3322/caac.21660. Accessed March 17, 2023.
   Google Scholar
• Oberman HA. Metaplastic carcinoma of the breast. A clinicopathologic study of 29 patients. Am J Surg Pathol. 1987;11(12):918–929. doi:10.1097/00000478-198712000-00002
   PubMed Web of Science ®Google Scholar
• IARC Publications Website. Breast tumours; 2023. Available from: https://publications.iarc.fr/Book-And-Report-Series/Who-Classification-Of-Tumours/Breast-Tumours-2019. Accessed March 17, 2023.
   Google Scholar
• Zubair M, Wang S, Ali N. Advanced approaches to breast cancer classification and diagnosis. Front Pharmacol. 2020;11:632079. doi:10.3389/fphar.2020.632079
   PubMed Web of Science ®Google Scholar
• Government Printing Office. RARE DISEASES ACT of 2002. 107th Congress Public Law 280, 1988 U.S. Government Printing Office; 2002:116.
   Google Scholar
• Weigelt B, Eberle C, Cowell CF, Ng CKY, Reis-Filho JS. Metaplastic breast carcinoma: more than a special type. Nat Rev Cancer. 2014;14(3):147–148. doi:10.1038/nrc3637
   PubMed Web of Science ®Google Scholar
• He X, Ji J, Dong R, et al. Prognosis in different subtypes of metaplastic breast cancer: a population-based analysis. Breast Cancer Res Treat. 2019;173(2):329–341. doi:10.1007/s10549-018-5005-6
   PubMed Web of Science ®Google Scholar
• Dreyer G, Vandorpe T, Smeets A, et al. Triple negative breast cancer: clinical characteristics in the different histological subtypes. Breast Edinb Scotl. 2013;22(5):761–766. doi:10.1016/j.breast.2013.01.009
   PubMed Web of Science ®Google Scholar
• Balkenhol MCA, Vreuls W, Wauters CAP, Mol SJJ, van der Laak JA, Bult P. Histological subtypes in triple negative breast cancer are associated with specific information on survival. Ann Diagn Pathol. 2020;46:151490. doi:10.1016/j.anndiagpath.2020.151490
   PubMed Web of Science ®Google Scholar
• Sanges F, Floris M, Cossu-Rocca P, et al. Histologic subtyping affecting outcome of triple negative breast cancer: a large Sardinian population-based analysis. BMC Cancer. 2020;20(1). doi:10.1186/s12885-020-06998-9
   Web of Science ®Google Scholar
• Liao HY, Zhang WW, Sun JY, Li FY, He ZY, Wu SG. The clinicopathological features and survival outcomes of different histological subtypes in triple-negative breast cancer. J Cancer. 2018;9(2):296–303. doi:10.7150/jca.22280
   PubMed Web of Science ®Google Scholar
• El Zein D, Hughes M, Kumar S, et al. Metaplastic carcinoma of the breast is more aggressive than triple-negative breast cancer: a study from a single institution and review of literature. Clin Breast Cancer. 2017;17(5):382–391. doi:10.1016/j.clbc.2017.04.009
   PubMed Web of Science ®Google Scholar
• Takala S, Heikkilä P, Nevanlinna H, Blomqvist C, Mattson J. Metaplastic carcinoma of the breast: prognosis and response to systemic treatment in metastatic disease. Breast J. 2019;25(3):418–424. doi:10.1111/tbj.13234
   PubMed Web of Science ®Google Scholar
• McCart Reed AE, Kalaw E, Nones K, et al. Phenotypic and molecular dissection of metaplastic breast cancer and the prognostic implications. J Pathol. 2019;247(2):214–227. doi:10.1002/path.5184
   PubMed Web of Science ®Google Scholar
• Tray N, Taff J, Adams S. Therapeutic landscape of metaplastic breast cancer. Cancer Treat Rev. 2019;79:101888. doi:10.1016/j.ctrv.2019.08.004
   PubMed Web of Science ®Google Scholar
• Samoon Z, Beg M, Idress R, Jabbar A. Survival and treatment outcomes of metaplastic breast carcinoma: single tertiary care center experience in Pakistan. Indian J Cancer. 2019;56(2):124–129. doi:10.4103/ijc.IJC_731_18
   PubMed Web of Science ®Google Scholar
• Rayson D, Adjei AA, Suman VJ, Wold LE, Ingle JN. Metaplastic breast cancer: prognosis and response to systemic therapy. Ann Oncol. 1999;10(4):413–419. doi:10.1023/A:1008329910362
   PubMed Web of Science ®Google Scholar
• Tseng WH, Martinez SR. Metaplastic breast cancer: to radiate or not to radiate? Ann Surg Oncol. 2011;18(1):94. doi:10.1245/s10434-010-1198-6
   PubMed Web of Science ®Google Scholar
• Hosmer DW, Lemeshow S, Sturdivant RX. Applied Logistic Regression. Vol. 398. 3rd ed. John Wiley & Sons; 2013.
   Google Scholar
• Saxena S, Rekhi B, Bansal A, Bagga A, Chintamani NS, Murthy NS. Clinico-morphological patterns of breast cancer including family history in a New Delhi hospital, India-a cross-sectional study. World J Surg Oncol. 2005;3:67. doi:10.1186/1477-7819-3-67
   PubMedGoogle Scholar
• Hashmi AA, Edhi MM, Naqvi H, Faridi N, Khurshid A, Khan M. Clinicopathologic features of triple negative breast cancers: an experience from Pakistan. Diagn Pathol. 2014;9(1). doi:10.1186/1746-1596-9-43
   PubMedGoogle Scholar
• Kumar S, Shaikh AJ, Rashid YA, et al. Presenting features, treatment patterns and outcomes of patients with breast cancer in Pakistan: experience at a university hospital. Indian J Cancer. 2016;53(2):230–234. doi:10.4103/0019-509X.197728
   PubMed Web of Science ®Google Scholar
• Ong CT, Campbell BM, Thomas SM, et al. Metaplastic breast cancer treatment and outcomes in 2500 patients: a retrospective analysis of a national oncology database. Ann Surg Oncol. 2018;25(8):2249–2260. doi:10.1245/s10434-018-6533-3
   PubMed Web of Science ®Google Scholar
• Saeed S, Asim M, Sohail MM. Fears and barriers: problems in breast cancer diagnosis and treatment in Pakistan. BMC Womens Health. 2021;21(1):1–10. doi:10.1186/s12905-021-01293-6
   PubMed Web of Science ®Google Scholar
• Balasubramanian A, Iyer P, Ranganathan R, et al. Metaplastic carcinoma of the breast: real-world outcome from a tertiary cancer centre in India. ecancermedicalscience. 2022;16. doi:10.3332/ecancer.2022.1429
   Web of Science ®Google Scholar
• Corso G, Frassoni S, Girardi A, et al. Metaplastic breast cancer: prognostic and therapeutic considerations. J Surg Oncol. 2021;123(1):61–70. doi:10.1002/jso.26248
   PubMed Web of Science ®Google Scholar
• Wolff AC, Hammond MEH, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast. J Clin Oncol. 2013;31(31):3997–4013. doi:10.1200/JCO.2013.50.9984
   PubMed Web of Science ®Google Scholar
• Yin L, Duan JJ, Bian XW, Yu S. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020;22(1):61. doi:10.1186/s13058-020-01296-5
   PubMed Web of Science ®Google Scholar
• Al-Hilli Z, Choong G, Keeney MG, et al. Metaplastic breast cancer has a poor response to neoadjuvant systemic therapy. Breast Cancer Res Treat. 2019;176(3):709–716. doi:10.1007/s10549-019-05264-2
   PubMed Web of Science ®Google Scholar
• Wong W, Brogi E, Reis-Filho JS, et al. Poor response to neoadjuvant chemotherapy in metaplastic breast carcinoma. NPJ Breast Cancer. 2021;7(1):96. doi:10.1038/s41523-021-00302-z
   PubMed Web of Science ®Google Scholar
• Pezzi CM, Patel-Parekh L, Cole K, Franko J, Klimberg VS, Bland K. Characteristics and treatment of metaplastic breast cancer: analysis of 892 cases from the National Cancer Data Base. Ann Surg Oncol. 2007;14(1):166–173. doi:10.1245/s10434-006-9124-7
   PubMed Web of Science ®Google Scholar
• Wu SG, Yang SP, Zhang WW, et al. The longitudinal risk of mortality between invasive ductal carcinoma and metaplastic breast carcinoma. Sci Rep. 2020;10(1). doi:10.1038/s41598-020-79166-5
   Web of Science ®Google Scholar
• Rizvi FH, Khan MK, Almas T, et al. Early postoperative outcomes of breast cancer surgery in a developing country. Cureus. 2020;12(8). doi:10.7759/cureus.9941
   Web of Science ®Google Scholar
• Afzal A, Khan KA, Chaudhary B, Folad L, Subhani AA, Mehr US. Five year experience of breast cancer surgeries. Pak J Med Health Sci. 2022;16(5):143–145.
   Google Scholar